XKRX
145720
Market cap259mUSD
Oct 08, Last price
40,350.00KRW
1D
0.88%
1Q
-3.12%
IPO
13.66%
Name
Dentium Co Ltd
Chart & performance
P/E
20.71
P/S
1.00
EPS
1,948.32
Div yield, %
—
Shrs. gr., 5y
-0.13%
Rev. gr., 5y
8.56%
Revenues
346.45b
-15.05%
Net income
16.80b
-76.89%
CFO
9.55b
-73.81%
Dividend
Mar 20, 2026600 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Dentium Co., Ltd., based in Seoul, South Korea, is a prominent global manufacturer and supplier of cutting-edge dental implant solutions. The company's extensive product range encompasses various dental implant systems, such as Superline, Implantium, Simpleline II, Slimline, Overdenture System, NR Line, and Implantium II. Dentium also develops a comprehensive assortment of surgical instruments, offering specialized kits for procedures like sinus lifts, osteotomy, and restoration, alongside individual tools such as harvest drills, surgical guides, and GBR systems. Additionally, they provide essential regenerative products like bone grafts, membranes, and tissue regeneration materials. Their portfolio is further enhanced by digital dentistry tools, laboratory supplies, iCT motors, and injections. Founded in 2000, the company initially operated as Biostech Co., Ltd. before adopting its current name, Dentium Co., Ltd., in August 2002.
Key people
Seung Wu Seo
Co-Chief Executive Officer, Director · since 2024
Byeong Ho Yoon
Co-Chief Executive Officer, Director · since 2024
Seong Min Jung
Director
Yin Jae Lee
Director
Seung Ryong Cho
Non-Executive Independent Director
Seong Ho Choi
Non-Executive Independent Director
Hui Taek Kim
Non-Executive Independent Director
Jong Ho Lee
Non-Executive Independent Director
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||